Obeticholic Acid

CymaBay Therapeutics achieved its targeted patient enrollment for the EHANCE trial, a phase 3 study of seladelpar for primary biliary cholangitis, and that the company is on track to complete full enrollment by the end of November.

Primary biliary cholangitis poses a significant challenge in hepatology, necessitating effective treatment strategies to improve patient outcomes and quality of life.